Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT04073602 2023-12-18

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Completed

19 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03809013 2023-11-27

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Completed

64 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05140512 2023-05-16

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Phase 1 Completed

23 enrolled

Genitourinary

Prostatic Neoplasms

NCT05856630 2023-05-12

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Phase 1 Unknown

24 enrolled

Genitourinary

Prostatic Neoplasms

NCT04563936 2021-08-26

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Phase 3 Completed

290 enrolled

Genitourinary

Prostatic Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Phase 1 Completed

89 enrolled

BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT03507166 2019-08-21

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Phase 2 Completed

43 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT02238366 2019-07-25

CHRONOS3

Completed

368 enrolled

Genitourinary

Prostatic Neoplasms

NCT00667537 2015-12-14

PK in Pts With HRPC & Skeletal Metastes

Phase 1 Completed

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT00918281 2014-06-09

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

Phase 2 Completed

70 enrolled 9 charts

BreastGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Sarcoma

Clinical Trials

A Study of MHB048C in Patients With Advanced Solid Tumors

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Spotlight

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

KEYNOTE F19

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

CHRONOS3

PK in Pts With HRPC & Skeletal Metastes

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection